RxDoctor Payments DataLook up a doctor →

Steven Domsky, MD

Advanced Heart Failure and Transplant Cardiology · Wynnewood, PANPI 1922200922

Payments from drug & device makers

$1,137,635in general payments, 2019–2025

Across 449 payments — averaging $2533.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$936K
  • Actelion Pharmaceuticals US, Inc.$73K
  • Pfizer$45K
  • Janssen Research & Development, LLC$33K
  • Actelion Pharmaceuticals, Ltd$16K
  • Bridgebio Pharma, Inc.$15K
  • plus $19K from 20 others

What the payments were for

  • Consulting fees$3,7202%
  • Speaking & faculty fees$128,25885%
  • Travel & lodging$7,6155%
  • Food & beverage$10,5327%
  • Education$4330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137,635 in reported general payments places this provider in the 95th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$384,485
Medicare patients
845
Services billed
3,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis160$3,874,000
OpsumitMacitentan120$1,504,957
AdempasRiociguat83$1,129,405
UptraviSelexipag43$728,299
Tyvaso DpiTreprostinil19$423,116
EntrestoSacubitril/Valsartan298$399,455
EliquisApixaban188$238,596
CamzyosMavacamten28$225,414
JardianceEmpagliflozin143$165,742
XareltoRivaroxaban85$104,332
FarxigaDapagliflozin Propanediol82$100,586
Ambrisentan29$52,337
Sildenafil Citrate87$38,832
Tadalafil13$20,772
BrilintaTicagrelor11$14,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$45,198$4,112,597348 claims
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$72,503$2,233,256163 claims
BayerAdempas$225$1,129,40583 claims
NovartisEntresto$178$399,455298 claims
E.r. Squibb & Sons, L.L.C.Camzyos$10,960$225,41428 claims
Boehringer IngelheimJardiance$389$165,742143 claims
AstraZenecaFarxiga, Brilinta$352$114,70993 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →